Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 302 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Alcohol Injection Clear all
Recruiting Phase 2 Interventional

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
347
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 265 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 2 Interventional

HTX-011 in Spinal Surgery

NCT04911062
View directory record Official record
Conditions
Post-Operative Pain, Lumbar Laminectomy
Interventions
Bupivacaine HCI without epinephrine, HTX-011, Luer Lock Applicator
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
12
States / cities
Phoenix, Arizona • Pasadena, California • Wichita, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 31, 2026, 10:35 PM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779
View directory record Official record
Conditions
Severe Asthma
Interventions
Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

NCT07428538
View directory record Official record
Conditions
Hepatitis
Interventions
Larsucosterol, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
92
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction

NCT02525718
View directory record Official record
Conditions
Breast Cancer
Interventions
Saline, 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 31, 2026, 10:35 PM EDT
Terminated Phase 2 Interventional

"The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors"

NCT05355597
View directory record Official record
Conditions
Musculoskeletal Diseases, Soft Tissue Mass
Interventions
Exparel Injectable Product, Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine)
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 31, 2026, 10:35 PM EDT
Terminated Phase 4 Interventional Results available

Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata

NCT05278858
View directory record Official record
Conditions
Alopecia Areata
Interventions
MedJet Device with intralesional triamcinolone
Combination Product
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
6 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 31, 2026, 10:35 PM EDT
Recruiting Phase 4 Interventional

Clinical Trial in Patients With Barth Syndrome- 4TAZPower

NCT07531251
View directory record Official record
Conditions
Barth Syndrome
Interventions
Elamipretide, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
5 Years to 55 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

NCT03556592
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Caffeine, Warfarin, Omeprazole, Metoprolol, Midazolam Hydrochloride
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Little Rock, Arkansas • Rogers, Arkansas • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

NCT00450372
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
ADI-PEG-20, Pharmacology Studies
Biological · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Early Phase 1 Interventional

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

NCT05891119
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Caffeine, Metoprolol, Midazolam, Warfarin, Vitamin K, Omeprazole, Rocatinlimab
Dietary Supplement · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Not applicable Interventional Results available

Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty?

NCT02276495
View directory record Official record
Conditions
Pain Management
Interventions
ACB Control - 20 ml saline injection for ACB, ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block, Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
Other · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual Atropine Bioequivalence by Route of Administration (SABER)

NCT06366087
View directory record Official record
Conditions
Atropine Bioequivalence
Interventions
Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Multi-System Analysis of Opioid Receptor Binding

NCT05528848
View directory record Official record
Conditions
Healthy, Opioid Use Disorder
Interventions
Carfentanil, C-11, Naloxone, Loperamide Hydrochloride
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

pAF for the Treatment of Osteoarthritis

NCT04886960
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Amniotic Fluid Injection, Standard of Care
Biological · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Early Phase 1 Interventional Results available

Inpatient Single Dose Interventions for Alcohol Use Disorder

NCT04562779
View directory record Official record
Conditions
Alcohol Use Disorder, Severe
Interventions
Naltrexone 380 MG, Ketamine Hydrochloride, Enhanced linkage
Drug · Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension

NCT05439460
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Phenylephrine, Epinephrine, Arginine Vasopressin
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 31, 2026, 10:35 PM EDT
Active, not recruiting Early Phase 1 Interventional

Local Multimodal Injection Versus Regional Anesthesia in Controlling Pain for Treating Rotational Ankle Fractures

NCT05019638
View directory record Official record
Conditions
Ankle Fractures
Interventions
Regional anesthesia group, Local multimodal analgesia group
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual vs IV Atropine Bioavailability Study

NCT04290039
View directory record Official record
Conditions
Toxic Effect of Organophosphate and Carbamate Insecticides
Interventions
Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

Preemptive Local Anesthesia in Vaginal Surgery

NCT00318292
View directory record Official record
Conditions
Pain, Postoperative
Interventions
bupivacaine and epinephrine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Oct 31, 2026, 10:35 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Tranexamic Acid in Nasal Mohs Reconstruction

NCT06057675
View directory record Official record
Conditions
Postoperative Bleeding, Skin Cancer Face
Interventions
Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine), Control (1% lidocaine with 1:100,000 epinephrine)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Analgesic Benefit of PECS Blocks for Biceps Tenodesis Shoulder Surgery

NCT02741713
View directory record Official record
Conditions
Biceps Tendonitis
Interventions
PECS "Pectoralis" 1 and 2 Blocks, Interscalene Block, Sham Block, Solution for Injection in Interscalene Block, Solution for Injection in Sham Block, Solution for Injection PECS Blocks
Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 31, 2026, 10:35 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Pain Perception During Intra-Articular Knee Joint Injection: What is the Effect of Needle Gauge and the Use of Ethyl Chloride?

NCT06865170
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee, Fear of Needles
Interventions
25 gauge needle, 22 gauge needle, +/- Ethyl Chloride Topical Aerosol Anesthetic
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
40 Years to 89 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Results available

Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids

NCT02798523
View directory record Official record
Conditions
Normal Physiology
Interventions
Methylprednisolone sodium succinate(Solu-Medrol), Topical methylprednisolone (Advantan emulsion 0 /1%)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 31, 2026, 10:35 PM EDT